CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL...
CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
Clovers COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, ...
Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19
Emmes announced that it conducted the data and statistical analysis for the third iteration of...
Ascelia Pharma presents study showing comparable efficacy of Orviglance lesion visualization and detection to...
Ascelia Pharma AB is presenting a study in which Orviglance® (manganese chloride tetrahydrate, former working...
Single Dose of Regen-Cov Provides Long-Term Protection Against COVID-19
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during...
Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for...
Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung...
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration
Antios Therapeutics, Inc. and Assembly Biosciences, Inc. announced that the companies have entered into a...
Moleculin obtains UK MHRA authorisation for Phase Ia trial of Covid-19 drug
Moleculin Biotech has obtained the UK Medicines and Healthcare Products Regulatory Agency (MHRA) authorisation to...
Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus Future Clinical Development in Sepsis/septic shock
Modus Therapeutics Holding AB , a company developing innovative treatments for patients with high unmet...
Brii Bio Initiates Submission of EUA Filing to U.S. FDA for BRII-196/BRII-198, , its...
Brii Biosciences Limited a multi-national company developing innovative therapies for diseases with significant unmet medical...
